InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Boundless Bio, Inc.

BOLD Clue Score31
United States Fiscal year ends December CIK 0001782303
$2.53 -1.94% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.53 +97.66% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 28 Mar 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2023Operating income−54.8Net income−49.4EPS, diluted−40.65Fiscal year 2024Operating income−73.3Net income−65.4EPS, diluted−3.85Fiscal year 2025Operating income−63.6Net income−58.2EPS, diluted−2.60
FY2023FY2024FY2025
Operating income −54.8 −73.3 −63.6
Net income −49.4 −65.4 −58.2
Growth
EPS, diluted −40.65 −3.85 −2.60

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2023Operating cash flow−46.9Capital expenditure−0.6Free cash flow−47.5Fiscal year 2024Operating cash flow−60.8Capital expenditure−2.5Free cash flow−63.4Fiscal year 2025Operating cash flow−46.7Capital expenditure−0.5Free cash flow−47.2
FY2023FY2024FY2025
Operating cash flow −46.9 −60.8 −46.7
Capital expenditure −0.6 −2.5 −0.5
Free cash flow −47.5 −63.4 −47.2
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2023Cash23.7Shareholders’ equity−127.1Fiscal year 2024Cash26.6Shareholders’ equity150.6Fiscal year 2025Cash17.9Shareholders’ equity98.7
FY2023FY2024FY2025
Cash 23.7 26.6 17.9
Shareholders’ equity −127.1 150.6 98.7

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Returns
n/a −43.4% −59.0%
−38.1% −31.7% −37.1%
Balance and payout
7.2% 27.0% 37.2%